Synendos Therapeutics AG

📍 Basel, Switzerland🗓 Founded 2019👥 9 employees💰 Last funded Apr 2021
Pharmaceutical Manufacturing🌐 synendos.com
Website LinkedIn
Synendos Therapeutics AG is a biopharmaceutical company founded in April 2019 as a spin-off of the University of Bern. Synendos develops an innovative therapeutic approach based upon first-in-class inhibitors (small molecules) that modulate a new drug target (not yet published). The inhibitors were designed and developed at the University of Bern starting from an in silico screening of 12 million compounds which was followed by a thorough med chem programme in collaboration with a CRO. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. Our mission is to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Switzerland
1
Spain
1
Frequently asked questions
Who invested in Synendos Therapeutics AG?
Synendos Therapeutics AG has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Synendos Therapeutics AG last raise funding?
The most recent investment in Synendos Therapeutics AG recorded on gritt.io was in April 2021.
When was Synendos Therapeutics AG founded?
Synendos Therapeutics AG was founded in 2019.
What industry is Synendos Therapeutics AG in?
Synendos Therapeutics AG operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Synendos Therapeutics AG based?
Synendos Therapeutics AG is headquartered in Basel, Switzerland.